DBDaniil Yu. Butylin

Daniil Yu. Butylin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniil Yu. Butylin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression

    by Alexander M. Reznik, Timur S. Syunyakov, Inessa Yu. Akhmerova, Daniil Yu. Butylin, Anastasia O. Vasilenko, Anton N. Gvozdetckii, Tagir R. Gizatullin, Galina V. Gilmanshina, Egor A. Golosov, Sergey A. Kolchev, et al.

    AIM: We endeavored to evaluate the efficacy of Lurasidone at doses of 40160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a Russian patient population. METHODS: One hundred sixty eight patients aged 1865 years old, who at the time of the start of the observation were being treated in a hospital or day hospital due to an exacerbation of paranoid schizophrenia accompanied by symptoms of depression, were prescribed lurasidone. Treatment with lurasidone and other concomitant drugs, their prescription, withdrawal, selection, and dose modifications were determined based on the indications for the use of those drugs and the recommended doses in the instructions, clinical need, and patient interests, rather than by the goals of the study. During the observation period, the severity of depressive symptoms according to the Calgary Depression Scale (CDSS) and that of psychotic symptoms according to the Positive and Negative Syndrome Scale (PANSS) were assessed six times (before the start of treatment and then on the 4th, 7th, 14th, 28th, and 42nd days). RESULTS: A statistically significant reduction in the severity of the symptoms was observed with the use of lurasidone in doses ranging from 40 mg to 160 mg per day. The fastest and most significant (p 0.001) reductions in the total PANSS and CDSS scores were observed with lurasidone 120 mg. A somewhat lower efficacy of lurasidone was observed at a dose of 160 mg. The largest reductions in the total PANSS and CDSS scores with lurasidone 120 mg were associated with the highest survival rate and the longest median time from treatment initiation to discontinuation or follow-up. The most commonly reported side effects with lurasidone in this study (nausea, akathisia, tremor and drowsiness) were consistent with the known safety profile of the drug. Adverse events in most cases were assessed as mild, or occasionally moderate. CONCLUSION: A six-week prospective observational study of the real-world clinical effectiveness of lurasidone in doses ranging from 40 mg to 160 mg per day established statistically and clinically significant improvements in both psychotic and depressive symptoms in patients with acute exacerbation of schizophrenia and associated symptoms of depression.


  • Clinical Features of Mental Impairments in Amyotrophic Lateral Sclerosis

    by D. Yu. Butylin, V. I. Krylov, O. I. Chesnokova, V. A. Mikheeva

  • Clinical features of mental disorders in amyotrophic lateral sclerosis

    by D.Y. Butylin, V.I. Krylov, O.I. Chesnokova, V.A. Mikheeva

    To investigate the clinical features of associated mental disorders in amyotrophic lateral sclerosis (ALS). Twenty-seven patients (9 men and 18 women, mean age 59.8±11.9 years) with the upper and lower motor neuron lesions were studied. The average duration of the disease at the time of examination was 3.2±2.4 years. Clinical psychopathological and follow-up methods were used. The severity of cognitive impairment was measured with the Edinburgh Cognitive and Behavioral ALS Screen (ECAS). The Montgomery-Asberg Depression Rating Scale (MADRS) was used to assess the severity of depression. Most patients (88.9%) had cognitive impairments. Amnestic disorders were primarily presented by hypo- and dysmnesia. These patients showed slow thinking, torpidity combined with circumstantiality and a tendency to detail. In addition to attentional fluctuations, we observed reduced attentional capacity, higher distractibility, and difficulty concentrating. The later stages of the disease were accompanied by the overall decline of thinking ability and intelligence with severe perseverations, and failure in the adequate self-assessment. More than half of the patients also developed the symptoms, such as dynamic aphasia, as well as functional speech disorders, i.e. gnosis and praxis. The vast majority of the patients had affective disorders (92.3%). So far as the symptoms of the underlying neurological condition worsened, the associated depressive symptoms prevailed (62.9%). Particular attention should be given to the clinical cases of ALS associated with psychotic disorders such as acute schizophrenia-like psychotic disorders. Presence of affective, cognitive and behavioral disorders, as well as a specific neuroimaging pattern, are considered as a whole as the manifestation of the behavioral variant of frontotemporal dementia (FTD). This provides support for the current opinion suggesting the similarity of ALS and FTD, which allows for considering these diseases as different phenotypic manifestations of a single pathological process.


  • Open Access

    Clinical and psychopathological features associated of obsessive and depersonalization disorders

    by V. I. Krylov, D. J. Butylin

    The results of the study showed the presence of definite syntropia between various clinical variants of obsessive and depersonalization disorders. Autopsychic depersonalization is most characteristic for contrast obsessions, whereas somatopsychic depersonalization is for re-control obsessions. Derealization or allopsychic depersonalization are more often observed in patients with obstructive extracorporeal threats. Depersonalization of change is equally characteristic for patients with schizotypal disorder and psychogenic personality development, whereas depersonalization of loss and splitting were observed only in cases of schizophrenic spectrum disorders.